According to Benzinga Pro, Globus Medical's peer group average for short interest as a percentage of float is 4.39%, which ...

Decades of market research shows that the best-performing stocks often have an 80 or higher RS Rating in the early stages of ...

Nationwide MOB sales were $1.5 billion in Q1. That was down 44% from Q4 2024. It marks the lowest quarter MOB sales since Q3 ...

Globus Medical currently trades at $75.69 per share and has shown little upside over the past six months, posting a middling ...

Learn more about whether Globus Medical, Inc. or LeMaitre Vascular, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

compete successfully (including without limitation success in convincing surgeons to use Globus Medical or Nevro products and ...

Globus Medical (NYSE:GMED) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. Summarizing their recent assessments ...

Globus Medical had set its initial 2025 sales forecast on a standalone basis at $2.66 to $2.69 billion, indicating a year-over-year increase of 6% to 7%, and an adjusted earnings per share (EPS) range ...